Drug Manufacturer Fraud Litigation - Monday, November 3, 2008 9:32 - 0 Comments

Federal judge certifies two nationwide classes in wholesale drug pricing cases

A federal judge in Boston has certified two nationwide classes and set the stage for two more trials in the massive, multidistrict wholesale drug pricing case against AstraZeneca and Bristol-Myers Squibb Co. The case alleges that the companies published fraudulently-inflated average wholesale drug prices. Their fraudulent conduct caused consumers and insurance companies to pay higher prices for branded and generic drugs used to treat serious illnesses like cancer and HIV. In an order, U.S. District Judge Patti Saris of the District of Massachusetts ruled that there would be a trial for each of the two classes and that each class period would range from January 1, 1991, to January 1, 2005.

Continue…